Table 1. Patient Characteristics.
Gender, lung function, parenchymal lung damage, and clinical microbiology results in study subjects.
| Subject | Brody Score | RUL BAL Clinical | ||||
|---|---|---|---|---|---|---|
| ID | Gender | FEV1 | RUL | RML | RLL | Microbiology |
| #1 | M | 90% | 18.0 | 9.0 | 9.0 | Pa, MSSA, MAC |
| #2 | M | 72% | 24.5 | 17.3 | 18.5 | Pa |
| #3 | F | 85% | 22.0 | 18.3 | 12.5 | Achromobacter |
| #4 | F | 56% | 18.8 | 12.5 | 8.3 | Pa |
| #5 | M | 92% | 20.8 | 10.5 | 10.8 | MSSA |
| #6 | M | 66% | 27.0 | 18.0 | 16.0 | Candida lusitaniae |
| #7 | F | 63% | 17.8 | 15.5 | 11.3 | Stenotrophomonas |
| #8 | M | 50% | 21.3 | 11.0 | 7.0 | N/A |
| #9 | M | 84% | 33.0 | 21.0 | 20.8 | Candida lusitaniae |
The Brody score, a composite assessment of bronchiectasis, peribronchial thickening, parenchymal disease, air trapping and mucus plugging (detailed information in S1 Table), was used to assess the level of lung damage in the right upper, middle and lower lobes (RUL, RML and RLL, respectively) in a CT scan taken within six months of the bronchoscopy procedure.
FEV1, forced expiratory volume in 1 second (% predicted) measured within four weeks of the bronchoscopy procedure. Clinical Microbiology Report results from analysis of RUL BAL are shown.
PA; Pseudomonas aeruginosa;
MSSA, methicillin-sensitive Staphylococcus aureus;
MAC, Mycobacterium avium complex;
N/A, not analyzed.